Perrigo Company plc Acquisition Costs, Period Cost
Perrigo Company plc (PRGO) reported Acquisition Costs, Period Cost of $1.90 million for the 3-month period ending 2013-09-28, per its 10-K filed 2015-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AcquisitionCosts · last filed 2015-08-13
- Perrigo Company plc acquisition costs, period cost for the quarter ending 2013-09-28 was $1.90M.
| Period end | Acquisition Costs, Period Cost 3 month |
|---|---|
| 2013-09-28 | $1.90M 10-K · filed 2015-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |